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To date no comparative trials have been done, to our knowledge, of fixed-dose artemisinin
combination therapies (ACTs) for the treatment of Plasmodium falciparum malaria in
pregnancy. Evidence on the safety and efficacy of ACTs in pregnancy is needed as these
drugs are being used increasingly throughout the malaria-affected world. The objective of this
study was to compare the efficacy, tolerability, and safety of artemether-lumefantrine, the most
widely used fixed ACT, with 7 d artesunate monotherapy in the second and third trimesters of
pregnancy.
Methods and Findings
An open-label randomised controlled trial comparing directly observed treatment with
artemether-lumefantrine 3 d (AL) or artesunate monotherapy 7 d (AS7) was conducted in Karen
women in the border area of northwestern Thailand who had uncomplicated P. falciparum
malaria in the second and third trimesters of pregnancy. The primary endpoint was efficacy
defined as the P. falciparum PCR-adjusted cure rates assessed at delivery or by day 42 if this
occurred later than delivery, as estimated by Kaplan-Meier survival analysis. Infants were
assessed at birth and followed until 1 y of life. Blood sampling was performed to characterise
the pharmacokinetics of lumefantrine in pregnancy. Both regimens were very well tolerated.
The cure rates (95% confidence interval) for the intention to treat (ITT) population were: AS7
89.2% (82.3%–96.1%) and AL 82.0% (74.8%–89.3%), p ¼ 0.054 (ITT); and AS7 89.7% (82.6%–
96.8%) and AL 81.2% (73.6%–88.8%), p¼0.031 (per-protocol population). One-third of the PCR-
confirmed recrudescent cases occurred after 42 d of follow-up. Birth outcomes and infant (up
to age 1 y) outcomes did not differ significantly between the two groups. The pharmacokinetic
study indicated that low concentrations of artemether and lumefantrine were the main
contributors to the poor efficacy of AL.
Conclusion
The current standard six-dose artemether-lumefantrine regimen was well tolerated and safe
in pregnant Karen women with uncomplicated falciparum malaria, but efficacy was inferior to 7
d artesunate monotherapy and was unsatisfactory for general deployment in this geographic
area. Reduced efficacy probably results from low drug concentrations in later pregnancy. A
longer or more frequent AL dose regimen may be needed to treat pregnant women effectively
and should now be evaluated. Parasitological endpoints in clinical trials of any antimalarial drug
treatment in pregnancy should be extended to delivery or day 42 if it comes later.
Trial Registration: Current Controlled Trials ISRCTN86353884
The Editors’ Summary of this article follows the references.
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Plasmodium falciparum infections in pregnancy account for a
high proportion of maternal mortality in malaria-endemic
countries [1,2], particularly in areas of low and unstable
transmission. The northwestern border of Thailand is an area
of low seasonal malaria transmission complicated by high
levels of multidrug resistance in P. falciparum. In this region in
1986 an estimated 1% of all pregnant women died from
malaria annually. Since then there has been no safe and
effective chemoprophylaxis that could be offered to pregnant
women. A system of weekly antenatal clinics (ANCs) was
therefore started. The ANCs provided early detection and
treatment of malaria and reduced both morbidity and
mortality [3]. Other malaria-preventive approaches in preg-
nancy such as insecticide-treated nets [4] and insect repel-
lents applied to the skin [5] did not show a signiﬁcant
preventive effect in this area. The therapeutic responses to
various antimalarial drug treatments of multidrug-resistant
falciparum malaria in pregnancy have been disappointing. In
this geographic area, quinine currently cures less than 60% of
pregnant patients [6,7]. This low cure rate is improved by
combining quinine with clindamycin, but the poor toler-
ability of quinine and the consequent poor adherence to 7 d
treatment regimens compromise effectiveness [8]. Short
course (3 d) ﬁxed-dose artemisinin combination therapies
(ACTs) are now recommended by the World Health Organ-
ization as ﬁrst-line treatments of falciparum malaria in all
endemic areas, and endorsed for use in the second and third
trimesters of pregnancy [9].
Artemether-lumefantrine given twice daily for 3 d (AL), is
the most widely used ﬁxed-dose ACT. It is effective against
multidrug-resistant P. falciparum malaria [10,11] but there are
no published efﬁcacy data in pregnancy [9]. AL has an
excellent safety proﬁle in non-pregnant humans [12]. In
animal studies, lumefantrine was neither mutagenic nor
embryotoxic [13]. Artemether, like all artemisinin derivatives,
can induce foetal resorption if given in high doses to
experimental animals during a narrow time window in early
gestation [14,15], although recent studies in primates showed
no teratogenic effects at dosages equivalent to those currently
recommended for antimalarial treatment [16].
In 1994 the northwestern border of Thailand became one
of the ﬁrst areas in which ACTs were deployed at scale. It took
until 2003 for sufﬁcient experience with artesunate treatment
in pregnancy to accumulate [17–19], and for sufﬁcient
conﬁdence to develop for ethical approval to be granted
for a treatment protocol evaluating AL in pregnancy. In 2006
WHO published guidelines recommending ACTs for the
treatment of malaria in the second and third trimester of
pregnancy whilst acknowledging the urgent need for more
information, on both safety and dosing [9]. There is
increasing evidence that the pharmacokinetic properties of
several antimalarial drugs, including artemisinin derivatives,
are affected signiﬁcantly in late pregnancy resulting in lower
blood concentrations. In the study area, current ﬁrst-line
treatment for falciparum malaria in pregnancy is quinine and
clindamycin in the ﬁrst trimester, and artesunate and
clindamycin in the second and third trimesters. These are
all 7-d treatments. A safe and effective shorter-course ﬁxed
dose ACT is needed to improve adherence to treatment and
ensure high cure rates in pregnancy. However there are
concerns that currently recommended doses of antimalarials
in pregnant women may be suboptimal [20–22]. The
hypothesis this study tested was that the AL would be
superior to artesunate monotherapy 7 d (AS7) in terms of
parasitological efﬁcacy in the treatment of uncomplicated P.
falciparum malaria in the second and third trimesters of
pregnancy. This randomised comparative trial included a
recently published nested substudy in which the pharmaco-
kinetic properties of artemether, dihydroartemisinin, and
lumefantrine [23] were characterised, followed by larger
evaluations of lumefantrine population pharmacokinetics
and day 7 drug level monitoring.
Materials and Methods
The CONSORT checklist and trial protocol can be found in
Text S1 and S2, respectively.
Participants Setting and Location
The women in this study attended the weekly ANC of
Shoklo Malaria Research Unit (SMRU). ANCs have been
conducted by the SMRU in Maela refugee camp since 1995,
for migrants south of Mae Sot since 1998, and for migrants
north of Mae Sot since 2004. These ANCs are attended by
women from approximately 120 km of the border area
between Thailand and Burma, north and south of the border
town of Mae Sot.
A blood smear to detect malaria is taken at each weekly
ANC visit (Figure 1). All parasitaemic episodes during
pregnancy are treated (Figure 2). In addition, women positive
for P. falciparum have blood spots taken for PCR genotyping
so that treatment efﬁcacy can be assessed accurately (Figure
2). The haematocrit is measured every 2 wk (Figure 2).
Women receive weekly ferrous sulphate (200 mg daily) and
folic acid (5 mg once weekly) prophylaxis or treatment for
anaemia, from the ﬁrst ANC consultation until delivery. All
medical and obstetric problems in pregnancy are investigated
and treated free of charge, resulting in low rates of self-
medication. All women are encouraged to deliver under
supervision in the SMRU facilities. Complicated deliveries
requiring cesarean section are referred to Mae Sot hospital
(1 h drive).
Eligibility
Patients with acute falciparum malaria in the second or
third trimesters of pregnancy were studied (Figure 2).
Patients with previous splenectomy, known chronic disease
(cardiac, renal, hepatic, haemoglobinopathy), inability to
follow the ANC consultation, history of alcohol or narcotic
abuse, imminent delivery, hyperparasitaemic and severe
malaria, inability to tolerate oral treatment, or allergy to
artemisinin derivatives or lumefantrine, were excluded from
the study. The aims and procedures of the study and the
anticipated beneﬁts, and potential inconveniences and
hazards were explained to each of the patients in her own
language. Witnessed written consent or thumbprint was
obtained from every patient participating in the study.
One of the ethical committees preferred that the inclusion
criteria only permit pregnant women in the second and third
trimester with a second (i.e., presumed recrudescent) episode
of uncomplicated P. falciparum malaria to participate in the
trial initially (Figure 2). Following a Data Safety Monitoring
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widened to allow any malaria episode, including the ﬁrst
episode in pregnancy in the second or third trimester, to be
included.
Ethics
The proposal was approved by three independent bodies:
The Ethical Committee of the Faculty of Tropical Medicine,
Mahidol University in Bangkok, the Oxford Tropical Re-
search Ethic Committee, and the Secretariat Committee on
Research Involving Human Subjects of the World Health
Organization. The protocol for this study was ﬁrst submitted
to ethical review boards in January 2003 and the ﬁrst of three
committees granted ethical approval on 7 February 2003. The
last gave approval on 6 February 2004. At the time of
protocol submission 7 d of quinine (ﬁrst trimester) and 7 d of
artesunate (second and third trimester) were used alone for
ﬁrst-line treatment of uncomplicated P. falciparum.T h e
second-line treatment was a 7 d combination of artesunate
and clindamycin. This explains why artesunate monotherapy
was chosen as the comparator for AL.
Interventions
Antimalarial drug treatments. Patients were randomised to
receive directly observed treatment with either (a) 3 d
artemether-lumefantrine (Novartis, Basel, Switzerland, 20/
120 mg artemether/lumefantrine): four tablets twice a day for
3 d, with 250 ml of chocolate milk containing 7 g of fat at each
dose (the drug was given at 0, 8, 24, 36, 48 and 60 h), or (b)
artesunate 2 mg/kg (50 mg tablets from Guilin Pharmaceutical
Factory, Guangxi, PRC) once daily for 7 d.
All patients were admitted for the duration of the treat-
Figure 1. Participant Flow in the Randomised Comparison of AS7 and AL
doi:10.1371/journal.pmed.0050253.g001
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was repeated in full if vomiting occurred within 30 min after
administration, or by a half dose if vomiting occurred
between 30 and 60 min.
Two batches of AL were used during the course of the
study. Drugs were stored mainly in the central pharmacy in
Mae Sot with a smaller amount being made available for use
in the ﬁeld. All drugs were stored in a cool, dry place.
After the consent procedure and before drug administra-
tion a full medical history and examination (including
obstetric evaluation) was carried out by a physician and
recorded. This included recording of duration of symptoms
before presentation and any drugs taken prior to arriving at
the clinic.
Daily malaria smears were made until the patient was
malaria smear–negative. Aural temperature was measured
daily while the patient was hospitalised. Patients under
treatment had daily clinical and obstetric examination, drug
administration, and recording of adverse events (AEs) on a
case record form (Figure 3). Thereafter patients were seen
weekly until delivery or day 42 if this occurred after delivery
(Figure 3). Reappearance of P. falciparum was treated with
artesunate (2 mg/kg per day) and clindamycin (300 mg three
times daily) for 7 d. Treatment of P. vivax infections was with
a standard chloroquine regimen (25 mg base/kg over 3 d).
Labour was monitored using the WHO partogram and data
on birth outcomes were collected. Low birth weight was
deﬁned as a birth weight measured in the ﬁrst 72 h of life of ,
2500 g and prematurity deﬁned as delivery before 37.0 wk of
gestation. Each baby was examined by a trained physician for
the presence of congenital abnormalities and neurological
development. Gestational age was estimated by ultrasound or
by the Dubowitz examination [24] for those with a late
ultrasound scan. All babies had a neonatal neurological
examination [25]. The neurological optimality score was
calculated for term singleton infants, born with cephalic
presentation and examined within 72 h of birth [25]. Infants
were followed monthly for growth assessment. Developmental
assessments were carried out at 3, 6, 9, and 12 mo to
determine the total developmental scores of the Shoklo
Developmental test [26] . Attainment of motor milestones was
evaluated at 12 mo (Figure 2).
AEs were deﬁned as signs and symptoms that occurred or
became more severe after treatment started. Symptoms were
screened for at each visit for 6 wk. The causal relationship
between the event and the study treatment was deﬁned as
unrelated, unlikely, possible, probable, or deﬁnite [27]. A
subgroup of 50 patients in each group was asked to provide a
complete blood count and biochemistry sample on admission
and at day 14. In addition, 50 patients in the AL group had
electrocardiographs (ECGs) recorded at baseline and 1 h after
the last dose. This was not a random sample as the equipment
was available at only one study site (Figure 3).
Laboratory Procedures
Blood smears (thin and thick ﬁlms) were prepared using
Giemsa staining and 200 ﬁelds were read before being
declared negative. Complete blood counts were determined
using a quality checked Sysmex pocH-100i automated
haematology analyzer and haematocrit read on a capillary
tube sample centrifuged at 1,500 rpm for 3 min. Blood spots
on Whatman 3M ﬁlter paper were prepared for PCR
genotyping by assessment of allelic variation at three loci
(merozoite surface proteins 1 and 2 and glutamate-rich
protein) to distinguish recrudescence from reinfection [28].
At delivery, malaria blood smears and PCR spots (from the
same sample) were prepared from the mother’s peripheral
blood, cord blood, placenta blood, and the baby’s heel prick
(Figure 2). The blood sampling of the placenta involved
making a 1 cm incision half-way between the site of cord
Figure 2. Schematic Diagram of Routine Antenatal Care and Basic Study Procedures in Pregnancy, at Delivery and Infant Follow-up
doi:10.1371/journal.pmed.0050253.g002
PLoS Medicine | www.plosmedicine.org December 2008 | Volume 5 | Issue 12 | e253 1702
RCT AL Versus AS7 Treatment in Pregnancyinsertion and edge of the placental disc on the maternal
surface. The blood that pooled into this incision was used for
malaria smear and PCR genotyping.
Pharmacokinetic Sampling
Initially a nested substudy in 13 patients was conducted to
characterise the pharmacokinetic properties of both arte-
mether (and dihydroartemisinin) and lumefantrine (Figure 3).
The results of the this pharmacokinetic evaluation have been
reported [23]. The efﬁcacy, safety, tolerability, and pregnancy
outcomes of AL in these women are included in this article.
This was followed by a nested population pharmacokinetic
study of lumefantrine (to be reported elsewhere) in 103
patients and collection of day 7 capillary plasma lumefantrine
samples in 85 patients (reported here) (Figure 3). Samples
were taken from a ﬁnger prick sample into four haematocrit
tubes. Plasma was separated and stored at  30 8C until
lumefantrine concentrations were analyzed using a validated
HPLC method described previously [29].
Objectives
The primary aim of this study was to assess the efﬁcacy of
AL in the treatment of uncomplicated falciparum malaria in
the second and third trimesters of pregnancy compared to
AS7 monotherapy, the standard ﬁrst-line treatment at the
time. The tolerability and safety of AL were also assessed as
compared to AS7. The AL efﬁcacy data were then related to
day 7 plasma concentrations of lumefantrine, known to be a
major determinant of parasitological response [30].
Outcomes
Parasitological cure. The primary endpoint was efﬁcacy
deﬁned as the P. falciparum PCR-adjusted cure rates assessed
at delivery or by day 42 if this occurred later than delivery, as
estimated by Kaplan-Meier survival analysis. The intention-
to-treat (ITT) population was deﬁned as all randomized
patients who took at least one dose of study treatment. The
per-protocol (PP) population was deﬁned as all patients
completing the expected number of days of treatment who
fuﬁl the inclusion/exclusion criteria of the protocol and who
were not absent for more than two consecutive weeks of
follow-up by day 42 or more than three consecutive weeks of
follow-up by delivery. Patients who were lost during follow-up
were censored at the last day seen. Patients who had a PCR-
conﬁrmed novel infection were censored on the day of
reinfection and classiﬁed as a treatment success up to that
day. Patients who had a PCR-conﬁrmed recrudescent
infection were censored on the day of parasite reappearance
and classiﬁed as a treatment failure. Both ITT and PP analyses
make the assumption that patients who were absent from the
weekly visits were malaria smear negative. Patients who
developed P. vivax infection and were therefore treated with
chloroquine, and patients treated with antibiotics with
antimalarial activity during follow-up were not censored in
the primary or day 42 study endpoint analysis.
Secondary endpoints for the mother were P. falciparum
PCR-adjusted cure rates assessed at day 42; cure rates for
reappearance of any malaria species (P. falciparum or P. vivax)
by delivery or day 42 if later; time to fever and parasite
clearance; mother peripheral blood, placenta blood, and cord
blood malaria parasite positivity rates at delivery; and the day
7 capillary plasma lumefantrine concentrations in the AL
group. Safety and tolerability endpoints included the
incidence of anaemia, ECG abnormalities, haematological
and biochemical disturbances, rates of vomiting and other
Figure 3. Schematic Diagram of Participant Follow-up after Randomization, Embedded Pharmacokinetic Studies, and Follow-up Scenarios
D42, day 42; D0, day 0; PCR, polymerase chain reaction, PF, P. falciparum; PV, P. vivax.
doi:10.1371/journal.pmed.0050253.g003
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tal assessment of neonates at birth and infants followed up to
1 y of age. The appearance of symptoms post-treatment was
examined after excluding patients who had the symptoms on
enrolment.
Sample size calculation. Based on previous drug efﬁcacy
studies in this area [11,18] AL was expected to be superior to
AS7. A sample size of 125 women in each group allowed
detection of a difference in cure rates of 16% and 4% to be
detected with 95% conﬁdence and 80% power, allowing a
10% drop-out rate.
Randomisation. Patients were assigned to one of the two
treatment groups in blocks of ten using a list of random
numbers. The randomization list was generated by an
independent statistician who was not involved in conducting
the study.
The treatment allocation was concealed in sealed envelopes
labelled with the study code by another person not involved
in conducting the study.
The study envelopes were sorted by code and kept at the
ﬁeld sites. Once a midwife identiﬁed a patient who met the
inclusion criteria she was assigned the next available code.
The envelope was then opened and the patient treated
according to the treatment allocation.
Blinding. Although initial treatment allocation was
blinded, administration of subsequent medication was not,
i.e., open-label. Laboratory staff reading the malaria smears
had no knowledge of the treatment received. All additional
sample investigation such as PCR genotyping, and patient
investigation such as neurological testing, was performed by
individuals who were blinded to the treatment allocation.
Statistical Methods
Normally distributed continuous variables were compared
using analysis of variance, and non-normally distributed
continuous variables were compared by means of the Mann-
Whitney U test. Differences in proportions were compared
using the Chi-squared test or Fisher’s exact test when
appropriate. Statistical programs used were SPSS for Win-
dows, version 11.0 (SPSS), and Epi Info, version 3.4.0 (US
Centers for Disease Control and Prevention).
Kaplan-Meier survival analysis was used for estimation of
PCR-adjusted cure rates and the log-rank test for comparison
of the primary study endpoint. The follow-up time was
calculated in days from enrolment to censoring, i.e., delivery
or day 42 (if later), parasite recurrence or loss to follow-up.
As some of the recruited patients had a previous malaria
infection documented during the pregnancy prior to enrol-
ment, the primary endpoint was re-examined after women
were classiﬁed according to their enrolment infection
(primary infection or PCR-conﬁrmed novel or recrudescent
infection). Kaplan-Meier survival analysis was repeated as
described previously (using the ITT population) with the
addition of strata: enrolled with a primary infection, novel
infection, or recrudescent infection.
Deﬁnitions used for analysis included the following: a case
of uncomplicated falciparum malaria was deﬁned as slide-
conﬁrmed P. falciparum malaria, with an asexual parasitaemia
(between six parasites per 500 white blood cells and 40 per
1,000 red blood cells [RBCs], approximately equivalent to 96–
150,000 parasites/ll), in the absence of signs of severe malaria.
Hyperparasitaemia was deﬁned by a parasitaemia of   40
parasites per 1,000 RBCs. Anaemia was deﬁned as a
haematocrit of less than 30%, and severe anaemia by a
haematocrit below 20%. Gametocyte carriage was measured
as the number of weeks during which gametocytes were seen
in the peripheral blood, divided by the total number of
follow-up weeks, and expressed per 1,000 person-weeks
(person–gametocyte-weeks), in patients who did not have
gametocytes on enrolment.
Results
Between 23 April 2004 and 29 August 2006, 252 women
with 253 episodes of acute falciparum malaria (one woman
randomised twice to AS7) were enrolled; 128 patients were
randomised to receive artesunate (AS7) and 125 to receive
artemether-lumefantrine (AL) (Figure 1). The average gesta-
tional age (range) of patients at enrolment was 24 (13–39) wk
(Table 1). Four patients did not receive a full course of
treatment: three became hyperparasitaemic in the ﬁrst 6 h,
requiring rescue treatment (including re-randomised woman)
and one developed artesunate allergy. Only eight (three AS7
and ﬁve AL) women defaulted from the study before the
delivery outcome was known. The last delivery date for the
study was 21 January 2007 and the last infant was followed up
on 12 February 2008.
Baseline Characteristics
There was no signiﬁcant difference in the baseline
characteristics of the patients in the two groups (Table 1).
The median (range) total artemether and lumefantrine dose
received per treatment course was 9.8 (1.5–13.7) mg/kg and
58.8 (8.7–82.3) mg/kg, respectively, and the corresponding
dose of artesunate in the comparator group was 14.0 (4.0–16.0)
mg/kg. More than half the patients had P. falciparum and/or P.
vivax infection treated during the pregnancy before entry to
the study (Table 2). There were 134 (AS7 group) and 134 (AL
group) infections of P. falciparum or P. vivax documented
before enrolment to the trial (Table 2). No signiﬁcant
differences were observed in the number of malaria infec-
tions, the total antimalarial treatments received or the PCR
genotyping classiﬁcation of the type of infection with which
the patient entered the study (Table 2). The majority of
antimalarial treatment before enrolment to the study was
quinine (and chloroquine for P. vivax) but 18 of the prior
treatments contained an artemisinin derivative (Table 2).
More patients in the AS7 group (22.7% [27/119]) than in
the AL (11.1% [13/117]) group delivered before day 42 of the
follow-up, p ¼ 0.018; however, the median (range) days of
follow-up until they were censored in the AS7 and AL groups,
both by delivery (or day 42 if later) by day 42, were not
signiﬁcantly different: 60 (7–193) d and 70 (3–188) d, p¼0.79;
and 42 (7–44) d and 42 (3–43) d, p ¼ 0.11, respectively.
Fever and Parasite Clearance
Patients in the AS7 and AL groups responded rapidly to
treatment and had similar median (range) fever and parasite
clearance times: 1 (1–2) d versus 2 (1–3) d, p¼0.20 and 2 (1–5)
d, for both groups, p ¼ 0.95, respectively.
Efficacy Endpoints
Before delivery (or day 42 if later), there were 74 episodes
of ﬁrst reappearance of P. falciparum, of which 30 (41%) (AS7
¼10, AL ¼20) were recrudescent infections, 44 (59%) (AS7¼
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reported as indeterminate. The results obtained for the ITT
population for PCR-adjusted cure rates have been detailed
for the primary (delivery or day 42 if later) and secondary
efﬁcacy endpoints (day 42), and indicate that that AS7 was
more efﬁcacious than AL (Figure 4; Table 4). The PP analysis
produced very similar results (Table 4).
For the PP analysis the number of patients censored for
weeks of sequential absence was similar in the AS7 and AL
groups: six in each group by day 42, and eight and 12 in each
group by delivery (or day 42 if later), p ¼ 1.000 for both
comparisons. The censored patients included two with late
parasite reappearance: one (AS7 group) PCR-conﬁrmed
recrudescent infection on day 51 and one (AL group) PCR-
conﬁrmed new infection on day 140. PP PCR-adjusted cure
rates by delivery (or day 42 if later) were again higher for AS7
than AL (Table 4) and likewise for PCR-adjusted cure rates by
day 42 (Table 4).
The median (range) interval to recrudescent infection, 27
(14–98) d, was shorter than the time to reinfection, 37 (15–
147) d, p ¼ 0.015. There was no signiﬁcant difference in time
to recrudescence between the AS7 and AL groups 32 (19–98)
d and 23 (14–63) d respectively, p¼0.14 (Table 3). Nearly one-
third (30% [9/30]) of recrudescent infections occurred after
day 42 (Table 3).
Cure rates based on classiﬁcation of enrolment infection.
Less than half 43.9% (111/253) of the patients who entered
the trial had a primary infection. The remaining patients (n¼
142) had recurrent infections at enrolment: of whom most
had one previous infection (n¼127), 14 had two, and one had
three previous episodes of P. falciparum within the same
pregnancy but before entry to the study (Table 2). PCR
genotyping of blood spots from previous episodes before
study enrolment permitted sub-classiﬁcation of these trial
entry infections into conﬁrmed recrudescent 28.5% (72/253),
new infections 19.4% (49/253) or unknown 8.0% (21/253); 11
AS7 and ten AL) (PCR indeterminate n ¼ 7, or PCR spot
unavailability or failure to amplify n ¼ 14). Patients with
unknown results were omitted from this subgroup analysis.
The PCR-adjusted cure rate for the patients who entered the
study with a recrudescent infection was signiﬁcantly higher
for AS7 compared to AL (Figure 5; Table 5). By contrast, the
PCR-adjusted cure rates of AS7 and AL in patients who
entered the study with new (Figure 5; Table 5) or primary
infections (Figure 5; Table 5) were very similar. Thus the
difference in cure rates in the overall analysis appears to be
explained by the inferior cure rates of AL in treating
recrudescent infections.
P. vivax Appearance
P. vivax occurred in 36.7% (47/128) and 29.6% (37/125) of
patients treated with AS7 and AL, respectively (p¼0.23), at a
median (range) of 29 (14–125) d and 34 (14–105) d following
treatment (p ¼ 0.47). After patients with P. vivax infection
during follow up were censored, the PCR-adjusted cure rates
for P. falciparum infection at delivery (or day 42 if later) using
Table 1. The Baseline Characteristics of Patients Analysed in the Trial
Characteristic AS7 AL
(One Dose per Day for 7 Days) (Two Doses per Day for 3 Days)
Number analyzed 128 125
Patients enrolled per site Refugee camp (%) 18.0 (23) 15.2 (19)
Migrants south of Mae Sot (%) 43.0 (55) 43.2 (54)
Migrants north of Mae Sot (%) 39.1 (50) 41.6 (52)
Age (years) 27 6 8 (14–44) 26 6 7 (14–42)
Weight, kg 49 6 7 (3–71) 50 6 6 (35–65)
BMI (body mass index) kg/m
2 21.4 6 2.7 (15.8–32.4) 21.5 62.0 (17.5–26.7)
Estimated gestational age, weeks 24.8 6 7.6 (13.1–39.4) 23.7 6 6.8 (13.1–39.2)
Proportion smoking 44.5 (57) 41.6 (52)
Gravidity, median 3 (1–11) 3 (1–13)
Parity, median 2 (0–9) 1 (0–9)
Proportion primigravida (%) 28.1 (36) 24.0 (30)
Parasitaemia, geometric mean (range)/ll 3,162 (48–158,489) 3,548 (65–457,088)
Haematocrit, % mean 6 SD 29.9 6 5.0 (19–47) 30.0 6 4.4 (20–42)
Proportion anaemic (%) 46.9 (60) 48.8 (61)
Median number PF episodes at enrolment 2 (1–4) 2 (1–3)
Proportion with gametocytes (%) 12.5 (16) 12.0 (15)
Proportion with a history of fever (%) 64.1 (82) 58.9 (73)
Fever duration before admission, d 2 (1–14) 2 (1–10)
Tympanic temperature, 8C 37.0 6 1.1 (35.1–39.9) 36.8 6 1.0 (35.0–39.8)
Proportion febrile (%) 58.6 (75) 57.6 (72)
Proportion foetal distress (%) 9.4 (12
a) 12.0 (15)
Proportion with headache (%) 77.3 (99) 80.0 (100)
Proportion with joint pain (%) 54.7 (70) 61.6 (77)
Proportion with muscle pain (%) 50.8 (65) 56.8 (71)
Proportion with anorexia (%) 52.3 (67) 58.4 (73)
Proportion with dizziness (%) 48.4 (62) 48.8 (61)
Data are mean 6 SD (range), unless otherwise indicated; proportions are presented as % (n).
aOne patient missing data.
doi:10.1371/journal.pmed.0050253.t001
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RCT AL Versus AS7 Treatment in Pregnancysurvival analysis were improved slightly: AS7 92.2% (95%
conﬁdence interval [CI] 86.1%–98.3%) versus AL 83.8% (95%
CI 76.1%–91.5%), p ¼ 0.045 (Table 4).
A survival analysis in which any subsequent malaria
infection (P. falciparum or P. vivax) appeared during follow-
up to delivery (or day 42 if later) was considered a ‘‘failure’’
resulted in low infection-free rates of AS7 31.9% (95% CI
20.1%–43.7%) and AL 38.1% (95% CI 28.1%–48.1%), p ¼
0.795, which illustrates the limited post-treatment prophy-
lactic effects of the two regimens. By day 50, 47.8% (121/253)
of patients had a reappearance of P. falciparum or P. vivax
(Figure 6).
Use of Other Drugs with Antimalarial Activity
There were 11 patients treated with drugs with antimalarial
activity (azithromycin, ciproﬂoxacin, erythromycin, or rifam-
picin); in four of these cases the treatment occurred after the
day of censoring for the primary study endpoint. There was
no signiﬁcant difference (p¼0.975) between the AS7 (3.1% [4/
128]) and AL (2.4% [3/125]) groups in the proportion of
patients treated with other antimalarials before censoring.
T h et r e n d si nc u r er a t e su s i n gs u r v i v a la n a l y s i sw e r e
unchanged when these patients were censored on the day
of receiving these drugs (unpublished data).
Anaemia
Nearly half the patients were anaemic at enrolment, with
similar proportions in the two groups (Table 1). The absolute
changes in haematocrit between enrolment and each of the
follow-up days (7–42)were calculatedfor each patient and were
summarised as mean (95% CI) values for each treatment group
(Figure 7). The drop in haematocrit from enrolment was
signiﬁcantly greater in the AS7 group at day 7 (p ¼ 0.037), but
therewas nosigniﬁcant differencebyday 14(p¼0.058)through
Table 2. Summary of Episodes of Malaria in Patients before Enrolment
Category Characteristic AS7 (One Dose
per Day for 7 Days)
AL (Two Doses
per Day for 3 Days)
Patients with P. falciparum infections before
enrolment
n ¼ 128 n ¼ 125
0 infections (%) 46.1 (59) 41.6 (52)
1 infections (%) 45.3 (58) 55.2 (69)
2 infections (%) 7.8 (10) 3.2 (4)
3 infections (%) 0.8 (1) 0
Antimalarial Treatment before enrolment n ¼ 135 n ¼ 134
Quinine 49.7 (67) 54.1 (73)
Artesunate 7.4 (10) 2.2 (3)
Dihydroartemisinin-piperaquine 2.2 (3) 0.8 (1)
Mefloquine-artesunate 0.7 (1) — (0)
Chloroquine (for P. vivax infections only) 40.0 (54) 42.9 (57)
Patients entering study with P. falciparum
or mixed (P. falciparum and P. vivax) infections
No prior infection, i.e., primary (%) 46.1 (59) 41.6 (52)
Recrudescent infections by PCR genotyping (%) 24.2 (31) 32.8 (41)
Novel infection by PCR genotyping (%) 21.1 (27) 17.6 (22)
Indeterminate by PCR genotyping (%) 2.3 (3) 3.2 (4)
Prior infection but no PCR genotyping available
a (%) 6.3 (8) 4.8 (6)
Proportions are presented as % (n).
aIncludes ten cases where no spot was available and four where the PCR failed to amplify.
doi:10.1371/journal.pmed.0050253.t002
Table 3. Summary of the Days of Reappearance (Recrudescent and Novel) According to the Treatment Groups until Delivery or Day 42
if Later
PCR-Confirmed Primary Outcome Group Data Day (d) of Reappearance Total
d14 d21 d28 d35 d42 After Day 42
a
Recrudescent AS7 N 0 3 2 1 0 d51,d60, d63, d98 10
Cumulative % 0 30.0 50.0 60.0 60.0 100.0
AL N 4 7 2 1 1 d49, d56 (2
b), d58, d63 20
Cumulative % 20.0 55.0 65.0 70.0 75.0 100.0
Novel AS7 N 0 3 4 3 3 d49, d70, d77, d84, d98, d119, d130,d147 21
Cumulative % 0.0 15.0 35.0 50.0 65.0 100.0
AL N 1 6 3 3 1 d63, d70 (3
b), d84, d98, d105, d109, d140 23
Cumulative % 4.5 31.8 45.5 59.1 63.6 100.0
aThe actual day of reappearance reported.
bNumber of patients in excess of n ¼ 1who showed reappearance that day.
doi:10.1371/journal.pmed.0050253.t003
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RCT AL Versus AS7 Treatment in Pregnancyto day 42 (p¼0.621). Nine patients (3.6%) were transfused (six
AS7 group and three AL group) for malaria-related anaemia.
Gametocyte Carriage
There was no signiﬁcant difference in the proportion of
patients with gametocytaemia on admission (Table 1). There
were ﬁve (AS7) and one (AL) patients who developed
gametocytaemia during follow-up (day 7 to day 42) with
carriage of 10 (95% CI 4–21) and 2 (95% CI 0–10) person–
gametocyte-weeksper1,000 person-weeks respectively,p¼0.13.
Day 7 Capillary Plasma Lumefantrine Levels
In total 85 patients in the AL group had capillary plasma
lumefantrine concentrations measured on day 7 following the
Figure 4. P. falciparum PCR-Adjusted Cure Rates at Delivery (day 42 if Later) (Left Graph) and at Day 42 of Follow-up (Right Graph) as Estimated by
Kaplan-Meier Survival Analysis
doi:10.1371/journal.pmed.0050253.g004
Table 4. P. falciparum PCR-Adjusted Cure Rates (%) for the Primary (Delivery or Day 42 if Later) and Secondary (Day 42) Study
Endpoints by Kaplan-Meier Analysis for the ITT and PP Populations
Population Analyzed Endpoint AS7 AL p-Value
a
ITT population n ¼ 128 n ¼ 125 —
Delivery (or day 42 if later) 89.2 (82.3–96.1) 82.0 (74.8–89.3) 0.054
Day 42 95.2 (91.5–97.1) 87.2 (81.1–93.2) 0.026
PP population n ¼ 125 n ¼ 124 —
Delivery (or day 42 if later) 89.7 (82.6–96.8) 81.2 (73.6–88.8) 0.031
Day 42 94.9 (91.0–98.8) 86.8 (80.5–93.1) 0.029
PCR genotyping–adjusted cure rates presented as % (95%CI). Significant p-values shown in bold.
ap-Value of log-rank test for difference in cure rates using Kaplan Meier survival analysis.
doi:10.1371/journal.pmed.0050253.t004
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RCT AL Versus AS7 Treatment in Pregnancystart of treatment. The geometric mean (range) lumefantrine
concentrations in patients who had subsequent recrudescent
P. falciparum infections (n ¼ 14) was 387 (164–551) ng/ml and
379 (134–1,320) ng/ml in those with recurrent novel infections
(n ¼ 17), and 423 (84.4–1,450) ng/ml in patients who had no
parasite reappearance (n ¼ 54), p ¼ 0.26 (Figure 8).
The lumefantrine concentration (LC) is known to be higher
in capillary plasma (CP) than venous plasma (VP). This
Figure 5. P. falciparum PCR-Adjusted Cure Rates (ITT) Assessed at Delivery (Day 42 if Later) as Estimated by Kaplan-Meier Survival Analysis after
Classification of the Enrolment Infection
Enrolment infections were classified by PCR genotyping into recrudescent, novel, or primary infections.
doi:10.1371/journal.pmed.0050253.g005
Table 5. P. falciparum PCR-Adjusted Cure Rates (%) in the ITT Population for the Primary (Delivery or Day 42 if Later) and Secondary
(Day 42) Study Endpoints after Stratification by the Type of Infection (also PCR Confirmed) on Enrolment
Endpoint after Stratification by the Type of Infection on Enrolment AS7 AL p-Value
a
Commenced treatment as a recrudescent infection
b n ¼ 31 n ¼ 41 —
Delivery (or day 42 if later) 91.1 (78.8–100) 73.9 (59.2–88.0) 0.034
Commenced treatment as a novel infection
b n ¼ 27 n ¼ 22 —
Delivery (or day 42 if later) 84.7 (67.5–100) 78.3 (59.3–97.3) 0.733
Commenced treatment as a primary infection n ¼ 59 n ¼ 52 —
Delivery (or day 42 if later) 89.0 (79.6– 98.4) 86.7 (76.7–96.7) 0.620
PCR genotyping–adjusted cure rates presented as % (95%CI). Significant p-value shown in bold.
ap-Value of log-rank test for difference in cure rates using Kaplan Meier survival analysis.
bPCR genotyping confirmed.
doi:10.1371/journal.pmed.0050253.t005
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RCT AL Versus AS7 Treatment in Pregnancyrelationship has been described previously by the following
equation derived from data obtained at this study site [31]:
lnLCCP ¼ 0:52 þ 0:95lnLCVP
In total 35% (30/85) of patients had day 7 capillary plasma
concentrations , 355 ng/ml (i.e., corresponding to 280 ng/ml
in venous plasma), a threshold previously associated at this
site with increased treatment failure rates in non-pregnant
patients [30].
The majority of patients with recrudescent infections had
admission parasitaemias over 5,000/ll and day 7 capillary
plasma lumefantrine concentrations below 500 ng/ml (Figure
9). This is reﬂected in the concentration of black diamonds
representing recrudescent infections in the lower right
quadrant of the scatter plot (Figure 9). All 21 (100%) patients
with levels over 600 ng/ml were cured, whereas 14 of 64 (22%)
patients with lower values had recrudescent infections (p ,
0.001).
Serious Adverse Events
There were 142 serious AEs (SAEs) including one maternal
death due to haemorrhagic shock from a ruptured uterus. This
was considered unrelated to the AL treatment she had
received 5 mo earlier. The only SAE that was deﬁnitely drug
related was a markedly raised parasite count on the second day
of AL treatment (parasitaemia day 0: 1.2% infected red blood
cell [IRBC] to day 1: 5.4% IRBC). This patient was monitored
with blood smears every 6 h for 24 h and, as the parasitaemia
then reduced, she did not require rescue treatment, although
she went on to have a PCR-conﬁrmed recrudescence on day
22. For the remaining 140 SAEs (64 AS7 and 76 AL), the
relationship to the treatment drug was rated as ‘‘possible’’ to
‘‘not related’’. The most common SAE in this study was
hospitalization (as required by protocol) to supervise the
treatment of a reappearance of P. falciparum infection (n¼101
episodes) which was more common in the AL (n¼59) than AS
(n ¼ 42) group. Nine patients were transfused for malaria-
related anaemia (three AL and six AS7), 12 patients were
admitted for febrile illness (four pyelonephritis, two each
group), one P. vivaxþurinary tract infection (AS7 group), two
acute respiratory infections (one each group), two scrub
typhus (AL group), two pulmonary tuberculosis (one each
group), one symptomatic P. vivax (AL group), and 18 patients
had obstetric problems (ﬁve threatened pre-term labour [three
AL and two AS7], three cesarean sections [all AL], ﬁve vacuum
extractions and two forceps deliveries [all AS7], one mid-
trimester abortion [AS7], and two stillbirths [one each group]).
Other Adverse Events
One patient experienced a mild allergy (urticarial rash)
after the second dose of artesunate which responded to oral
Figure 6. Malaria (P. falciparum or P. vivax) Cure Rates Assessed at
Delivery or Day 42 (if Later) as Estimated by Kaplan-Meier Survival
Analysis
doi:10.1371/journal.pmed.0050253.g006
Figure 7. The Absolute Change in Haematocrit between Admission and Each Follow-up Day from 7 to 42
Change was calculated for each individual patient and summed as mean and 95% CI for the two treatment groups.
doi:10.1371/journal.pmed.0050253.g007
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RCT AL Versus AS7 Treatment in Pregnancychlorpheniramine and stopping artesunate. Early vomiting
occurred in 1.2% (3/253) of patients, two AL and one AS7, all
with the ﬁrst dose and for each the repeat dose was tolerated.
The patients who had blood counts and biochemistry
evaluated had a history of less fever and less symptoms on
admission, than the patients who were not studied (p , 0.05).
There was no signiﬁcant difference between the groups’
haematological and biochemical parameters at baseline. In
the individual paired analysis there was no signiﬁcant
difference in the proportion of patients in each group who
developed abnormal values on day 14 when they were not
present on enrolment.
There was no difference in the baseline characteristics of
patients who volunteered for ECG examination and those
who did not have these performed. There were 51 patients
treated with AL who had paired ECG examination (prior to
treatment and 1 h after the last dose) with no clinically
relevant abnormalities.
The only symptom that differed signiﬁcantly between the
groups in follow-up, when it was not present on enrolment,
was tinnitus, which was more frequent in the AS7 group 8.5%
(7/82) compared to 0% (0/86) in AL group, p ¼ 0.006 (Fisher’s
exact). Tinnitus in these seven patients was short-lived (, 1
wk) and resolved in all cases.
Birth Outcome
Data on birth outcome were documented for 96.8% (244/
252) of women and not available for 3.2% (8/252) who were
lost to follow-up before the end of pregnancy. Amongst the
women with a known outcome there were 99.6% (243/244)
births and 0.4% (1/244) abortions. There were 239 singleton
births including two stillbirths and four twin births (all of
whom were normal, alive, term infants of low birth weight in
87.5% [7/8] of cases).
There were no signiﬁcant differences in the major birth
indicators between the groups including birth weight,
gestation, congenital abnormalities, and the newborn neuro-
logical optimality score (Table 6). The abortion occurred at
16.6 wk gestation in a 35-y-old, smoker, gravida 8, parity 5, in
the AS7 group and was considered unlikely to be drug related
as foetal distress was present before the drug was given. Both
stillbirths were externally normal. One (AS7 group) was
associated with histopathologically conﬁrmed chorioamniotic
inﬂammation due to recurrent, culture-conﬁrmed Escherichia
coli urinary tract infection, and the other (AL group) possibly
related to consanguinity (marriage to a second cousin).
Placental Malaria Infection
Malaria smear and blood spots for PCR genotyping on
maternal peripheral blood, cord blood, placental blood, and
the baby’s peripheral blood were reported for 70% (169/243)
of birth outcomes (including twins and excluding the
abortion case). Concordance between microscopy and PCR
detection of P. falciparum in peripheral and placental speci-
mens was very high (Table 7). All the women with positive
placenta samples had at least one reappearance of P.
falciparum during follow-up after study enrolment. The single
discrepant result between mother peripheral and placental
blood occurred in a woman who delivered on day 7 of
retreatment with artesunate and clindamycin: peripheral
parasitaemia had cleared but placental parasitaemia was still
detectable by PCR and microscopy. In contrast, PCR detected
three positive cord blood samples when microscopy was
negative. Positive cord blood samples all occurred in women
with active infection at delivery (placental and peripheral
smear positive), one on day 2 of treatment. All infants were
peripheral blood negative (microscopy and PCR) at birth.
Two of the cord blood–positive infants remained negative by
weekly peripheral smear by day 28. The remaining infant,
who became ill on day 20 of life, was P. falciparum positive by
microscopy and PCR. Parasite genotyping of the infant blood
matched the mother, cord, and placental DNA of the
infection at the time of delivery.
Figure 8. Scatterplot of Lumefantrine Concentration from Capillary
Sampling on Day 7
Data are grouped according to the endpoint (recrudescent, novel
infection or primary infection) after AL treatment. Geometric mean (ng/
ml) displayed within text box.
doi:10.1371/journal.pmed.0050253.g008
Figure 9. Scatterplot of Day 7 Lumefantrine Concentrations Versus
Enrolment Parasitaemia
Units are ng/ml. Data on y-axis are from capillary sampling; x-axis is the
enrolment parasitaemia (per ll). Markers identify the primary efficacy
endpoint of AL treatment: recrudescent (solid diamonds), novel
infections (open diamonds) and no reappearance (3).
doi:10.1371/journal.pmed.0050253.g009
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RCT AL Versus AS7 Treatment in PregnancyThree women had peripheral blood P. vivax parasitaemia at
delivery, and one of these had P. vivax positive placental tissue
by microscopy. No cord or baby malaria smears were positive
for P. vivax by microscopy.
Infant Follow-up to 1 Year of Life
All four sets of twins (eight babies) survived to 1 y and were
developing normally. Of the singleton infants, 82.2% (195/
237) were followed up for   9 mo. The main reason for loss to
follow-up was leaving the study area. Overall 77.5% (93/120)
of AS7 and 72.6% (85/117) of AL infants were evaluated at 12
mo, p ¼ 0.32. There was no signiﬁcant difference in the
median months of follow-up (unpublished data). A total of
nine infants died among the 237 infants followed to 1 y, an
overall infant mortality rate of 38 per 1,000 live-born
singletons. Signiﬁcantly more infant deaths occurred in the
AS7, 6.7% (8/120) than AL 0.9% (1/117) group, p¼0.036. Five
infant deaths occurred in the ﬁrst month of life (day 0–32),
three of which were related to prematurity (27.3, 29.4, and
34.4 wk), while the other two were from pneumonia in the
ﬁrst 2 wk of life in term infants. Of the remaining infants one
was premature (33.1 wk) and died of sepsis at 3 mo. The
mother was diagnosed with TB and HIV postpartum. One
child died from diarrhoea at 4 mo, one from suspected
Table 6. Birth Outcomes in Each Group
Group Parameter AS7 AL p-Value
Liveborn singletons n ¼ 120 n ¼ 117 —
Estimated gestational age, wk 39.5 6 2.2 (27.3–42.4) 39.7 6 1.6 (31.5–43.5) 0.533
Proportion premature (%) 8.3 (10) 2.6 (3) 0.084
Proportion male infants (%) 47.5 (57) 51.3 (60) 0.604
Congenital abnormality (%) 3.3 (4) 2.6 (3) 1.000
Human tail Hemimegaloencephaly —
Amniotic banding Multiple absent nails, upper and lower limbs —
Persistent undescended testis — —
Congenital cataracts — —
— Syndromic: probable Alagille’s (genetic) —
Liveborn infants weighed
in the first 3 d of life
n ¼ 101 n ¼ 99 —
Birthweight, g 2,805 6 428 (1,200–3,570) 2,861 6 386 (1,700–3,780) 0.326
Proportion low birth weight (%) 19.8 (20) 14.1 (14) 0.348
Proportion term and low birth weight (%) 14.0 (13) 13.5 (13) 1.000
Head circumference, cm 31.9 6 1.6 (25.5–-36) 32.2 6 1.7 (26–36) 0.279
Arm circumference, cm 9.5 6 1.0 (6.3–12) 9.8 6 1.0 (6.5–12.5) 0.071
Length, cm 48.3 6 2.5 (39.5–53) 48.5 6 2.2 (39.5–54) 0.496
Newborn neurological optimality score,
median (range), n
17 (6–20), n ¼ 87 17 (6–20), n ¼ 94 0.401
Data are mean 6 SD (range) and (n) unless otherwise stated. Proportion presented as % (n).
doi:10.1371/journal.pmed.0050253.t006
Table 7. Summary of Microscopy and PCR on Delivery Samples from the Mother, Placenta, Cord, and Newborn
Sample Outcome Microscopy Smear PCR
AS7 AL Total % Microscopy Smear AS7 AL Total %PCR
Mother’s peripheral blood Total 86 83 169 100.0 86 83 169 100.0
Negative 83 78 161 95.3 85 79 164 97.0
P. falciparum 14
a 5 2.9 1 4a 5 3.0
P. vivax 2 1 3 1.8 N.A. N.A. N.A. N.A.
Placental blood Total 78 78 156 100.0 86 82 168 100.0
Negative 76 73 149 95.5 85 77 162 96.4
P. falciparum 15
a 6 3.8 1 5a 6 3.6
P. vivax 1 0 1 0.6 N.A. N.A. N.A. N.A.
Cord blood Total 78 74 152 100.0 86 82 168 100.0
Negative 78 74 152 100.0 86 79 165 98.2
P. falciparum 0 0 0 0.0 0 3 3 1.8
P. vivax 0 0 0 0.0 N.A. N.A. N.A. N.A.
Newborn blood Total 82 83 165 100.0 85 83 168 100.0
Negative 82 83 165 100.0 85 83 168 100.0
P. falciparum 0 0 0 0.0 0 0 0 0.0
P. vivax 0 0 0 0.0 N.A. N.A. N.A. N.A.
aThe single discrepant result between mother peripheral and placental blood occurred in a woman who delivered on day 7 of retreatment (AC7): peripheral parasitaemia had cleared but
placental pararasitaemia was still detectable by PCR and microscopy.
doi:10.1371/journal.pmed.0050253.t007
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RCT AL Versus AS7 Treatment in Pregnancyintraventricular haemorrhage on a background of Allagile’s
syndrome at 7.5 mo (AL group), and one from suspected beri-
beri at 10.5 mo. There was no difference between the infants
in the groups in growth parameters or developmental
parameters assessed by the Shoklo Developmental Scores at
3, 6, 9 (unpublished data), and 12 mo (Table 8).
Of 668 morbid episodes treated in 196 infants in the ﬁrst
year of life, acute respiratory infection 51.9% (347), skin
infection 18.3% (122), and malaria 13.0% (87 including one
twin) were the most common diagnoses. Malaria affected
approximately one-ﬁfth of infants in the ﬁrst year of life: AS7
16.1% (19/118) and AL 19.0% (22/116), p ¼ 0.61. The median
(range) age of ﬁrst P. falciparum was 29.9 (2.9–51) wk and 30.1
(3.4–44.3) wk for the ﬁrst P. vivax infection. There was also no
signiﬁcant difference in the species, the median days to the
ﬁrst episode, or the total number of episodes in the ﬁrst year
of life (unpublished data), according to the mother’s treat-
ment group. The relative risk for recurrent malaria in the
ﬁrst year of life was signiﬁcantly higher with P. vivax than P.
falciparum: 2.9 (95% CI 1.2–7.0); 67.7% (21/31) versus 23.5% (4/
17), p ¼ 0.008.
Discussion
ACTs are now recommended as ﬁrst-line treatment for
falciparum malaria throughout the malaria-endemic world,
and are now speciﬁcally recommended for the treatment of
falciparum malaria in the second and third trimesters of
pregnancy. This is a pragmatic compromise, as ACTs may
become the only available effective antimalarials, pregnant
women are at increased risk from falciparum malaria, and the
evidence to date indicates that artemisinin derivatives are
safe in later pregnancy. This is, to our knowledge, the ﬁrst
randomised controlled trial of ﬁxed-dose ACT in the treat-
ment of uncomplicated malaria in pregnancy. Artemether
with lumefantrine was very well tolerated with no adverse
effects either for the mother or for the foetus, yet its efﬁcacy
was lower than expected. Both artesunate monotherapy for
7 d and the standard 3 d regimen of artemether and
lumefantrine resulted in cure rates below the 90% efﬁcacy
threshold recommended by WHO [9]. Cure rates are likely to
be even lower outside the setting of a trial when all doses
cannot be directly supervised. Failure rates were over twice as
high as those in non-pregnant adults, given the same dose in
this same location, for whom AL cure rates consistently
exceed 95% [11]. The cure rates in pregnant women are lower
than observed in young children in this area, a patient group
with little or no immunity, which suggests that the poor
therapeutic response is not explained by the malaria-speciﬁc
immunosuppression of pregnancy. The signiﬁcantly lower
cure rates with AL were largely explained by the difference in
cure rates for recrudescent infections (i.e., women presenting
with a recrudescence of a previous infection). This study
initially recruited women with a recurrent P. falciparum
infection only, as there had been no previous experience to
establish the safety of AL in pregnancy. This trial was not
originally designed to compare cure rates in recrudescent
with those in new or primary infections (Figure 5; Table 5),
but the exploratory analysis shows a clear superiority of AS7
over AL in this particular subgroup. There was no difference
in efﬁcacy between AL and AS7 in the treatment of primary
or new infections. This difference between primary and
recrudescent infections presumably reﬂects reduced class
susceptibility of the recrudescent infections to quinine,
meﬂoquine, and lumefantrine [32]. Although AL is not
routinely used in the study area, there is cross-resistance
with meﬂoquine, which is combined with artesunate in the
ﬁrst-line treatment in the non-pregnant population. Resist-
ance is associated with an increase in Pfmdr1 copy numbers
[33–35]. Parasites with increased Pfmdr1 copy number are also
slightly less sensitive to artemisinin derivatives, although the
differences are much less than for lumefantrine [36].
The poor cure rate of AL in pregnant compared to non-
pregnant patients probably results from the lower drug
concentrations of both component drugs. The pharmacoki-
netic properties of both artemether and lumefantrine in later
pregnancy are altered substantially. As with several other
antimalarial drugs, plasma concentrations of artemether, its
principal metabolite dihydroartemisinin, and lumefantrine
are reduced in pregnant women [23,37–39]. This was shown in
the conventional pharmacokinetic study [23] embedded into
the early phase of this trial, and is reﬂected again by the
relatively low day 7 capillary plasma lumefantrine concen-
trations.
We have shown previously that low plasma lumefantrine
levels, reﬂected by the area under the plasma concentration
time curve (or its surrogate, the day 7 level), and parasitaemia
Table 8. Outcome of Infants Followed up to the End of the First Year of Life in Each Group
Data Category Parameter AS7 AL p-Value
Characteristics of liveborn singletons seen at 12 6 1m o Number n ¼ 93 n ¼ 85 —
Age, mo 12.0 6 0.15 (11.0–12.0) 12.0 6 0.11 (11.0–12.0) 0.612
Weight, g 8,579 6 1,088 (6,300–11,000) 8,693 6 1,197 (6,000–11,500) 0.509
Length, cm 71.7 6 4.2 (43.0–80.0) 72.4 6 3.1 (64.0–80.0) 0.155
Head circumference, cm 44.3 6 3.4 (40.0–71.0) 44.0 6 1.5 (40.0–49.5) 0.372
Arm circumference, cm 14.7 6 1.1 (12.0–17.0) 14.6 6 1.2 (12.0–17.4) 0.679
Developmental scores, median (range) Coordination score 30 (15–34) 30 (7–34) 0.810
Tone score 12 (7–14) 12 (9–13) 0.405
Behaviour 15 (9–15) 15 (10–15) 0.461
Motor milestones 20 (12–24) 20 (1–24) 0.337
Social and speech 11 (7–12) 11 (7–13) 0.979
Data are mean 6 SD (range) unless otherwise stated.
doi:10.1371/journal.pmed.0050253.t008
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studies conducted in non-pregnant patients [30]. Thus
patients with lower drug levels and higher parasitaemias are
most likely to fail treatment (Figure 9). Where drug resistant
parasites are prevalent, the combined effects of low anti-
malarial drug levels and the attenuated antiparasitic immun-
ity in pregnancy in patients with heavier parasite burdens
(itself a reﬂection of reduced immunity against the infecting
parasite population) increase the risk of treatment failure.
The need in malaria-endemic areas for a safe and effective
drug with an adequate post-treatment prophylactic effect in
pregnancy is clearly demonstrated by the fact that half of the
patients in this study had recurrent malaria infection within
50 d. All women who had positive placental blood at delivery
had parasite reappearance after randomization.
Several factors contribute to the poorer treatment re-
sponses during pregnancy; P. falciparum parasites sequester in
the placenta and so the parasite burden is underestimated,
antiparasitic immunity is compromised, and antimalarial drug
levels are generally lower. This study shows that guidelines for
deﬁning antimalarial efﬁcacy [40,41] in non-pregnant patients
may not be applicable to pregnancy. Nearly one-third of PCR
genotyping–conﬁrmed recrudescent infections occurred after
day 42, whereas in non-pregnant patients treated with these
drugs nearly all recrudescences occur within 42 d. Importantly
this happened equally with artesunate and artemether-
lumefantrine. One woman harboured a single infection at
sub-patent densities for 3 mo following artesunate. Thus
pregnant women can harbour recrudescent infections for
protracted periods. This has been reported previously in Asia
[6,28] and more recently in Africa [42]. The duration of follow-
up in all antimalarial drug trials in pregnant women should be
extended at least to delivery, or day 42 if this comes later.
In contrast to high-transmission settings, microscopy of the
placental smear did not add to the diagnostic yield. P.
falciparum PCR genotyping of maternal peripheral and
placental blood at delivery did not detect any submicroscopic
infections. All cases of placentas that were positive by PCR
were found in mothers with a positive peripheral blood smear
or very recently treated positive peripheral blood smear.
Early detection and treatment of malaria by active weekly
screening of maternal peripheral blood smears appears to be
a very reliable method to detect P. falciparum malaria in
pregnancy in this area of low transmission.
There were few adverse events in this study and these were
mainly unrelated to treatment. Anaemia is a signiﬁcant
adverse effect of malaria in pregnancy [43]. Artemisinin and
its derivatives temporarily suppress erythropoeisis, but this
‘‘trades off’’ against the beneﬁt of rapidly reducing para-
sitaemia and thereby reducing malaria-associated haemolysis.
The slightly lower levels of haematocrit and haemoglobin at
day 7 in the AS7 group were expected because of the longer
haematopoietic suppression from the 7 d regimen [44]. This
was not clinically signiﬁcant as there was no difference in day
42 haematocrit levels, or ﬁnal haematocrit before delivery.
No pregnant women or newborns in this study died from
malaria. The newborn anthropometric results and neuro-
logical scores (Table 5) were very similar in the two groups
and are consistent with having multiple malaria infections in
pregnancy [18,43,45,46]. The better efﬁcacy of AS7 compared
to AL did not result in improved birth outcomes in the AS7
group nor would one expect it to, as this study was not
powered to detect such differences. This was a study
conducted in the second and third trimesters so any
congenital abnormalities are most unlikely to be drug related
and the rates were similar to previously reported studies in
this area [18,45]. Although there were signiﬁcantly more
infant deaths in the AS7 group, these deaths were unrelated
to treatment. The growth parameters and Shoklo devel-
opmental score of the infants during and up to 1 y of follow-
up were also reassuring. Overall the 252 women in this study
were treated with a total of 362 artemisinin-based treatments
for slide-conﬁrmed P. falciparum infections before and during
this study. This provides further reassuring safety data on the
use of artemisinins in the second and third trimesters of
pregnancy; however, further large-scale assessments are
needed to conﬁrm this safety proﬁle.
One of the limitations of this trial includes the lack of
blinding to antimalarial treatment administration. A placebo
for this trial would have been difﬁcult as the two regimens
were very different. The embedded pharmacokinetic sam-
pling would have been impossible without unblinding the
trial or sampling women from both groups to maintain
blinding, which would be unethical. The ad-hoc analysis
shows differences within the strata, rather than simply
between groups, which suggests the lack of blinding did not
inﬂuence the efﬁcacy results.
Immunity contributes signiﬁcantly to treatment outcomes.
It is probable that treatment responses to AL would be better
in higher-transmission settings. But in this setting where P.
falciparum is relatively resistant and transmission intensity
(and therefore immunity) is low, the cure rates with AL in
pregnancy are unsatisfactory. A dosage increase is needed. A
major drawback is that lumefantrine absorption has been
shown to be dose-limited [47], so simply increasing the
individual doses is unlikely to result in higher cure rates. A
longer or more frequent AL treatment course should now be
evaluated. Importantly, the most favourable efﬁcacy results
for this drug in non-pregnant patients on the Thai-Burmese
border were obtained by giving six doses over 5 d [48]. A 5 d
regimen would provide artemether exposure over three
parasite asexual cycles and 67% more lumefantrine. Pharma-
cokinetic dose evaluation studies on higher AL dose regimens
should now be performed. Adequate cure rates for falcipa-
rum malaria in pregnancy will only be achieved when the
doses are optimised speciﬁcally for pregnancy. Antimalarial
efﬁcacy studies in pregnancy are more complex than in non-
pregnant patients. Lengthy follow-up is needed both to
capture delayed recrudescence and for the assessment of the
newborn. A safe and effective, short course, artemisinin-
based combination treatment for uncomplicated P. falciparum
malaria in pregnant women has yet to be found.
Generalisability
Our results do not indicate that the conventional regimen
of AL cannot be used to treat pregnant women with
uncomplicated falciparum malaria in other endemic regions.
However, they show that in an area of multidrug resistance,
the lower lumefantrine plasma levels found in pregnant
women will result in a lower parasitological efﬁcacy. In areas
of higher endemicity where multigravid pregnant women
have some protection from acquired premunition, the
conventional regimen of AL, i.e., two doses per day for 3 d,
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netics) are in progress at the time of writing.
Overall Evidence
There are no data on a direct comparison of the
pharmacokinetics of lumefantrine in pregnant and non-
pregnant women. The only comparable pharmacokinetic
data from the same population and the same pharmacology
laboratory are from adults (mostly males), and these were
used in the present discussion. The results of the population
kinetic study of lumefantrine in the pregnant women of this
study will be presented elsewhere. Preliminary analysis
conﬁrms the ﬁndings of the initial pharmacokinetic study
[23] and show that plasma levels of lumefantrine are generally
lower in pregnant women.
Conclusions
The current standard six-dose artemether-lumefantrine
regimen was well tolerated and safe in pregnant Karen
women with uncomplicated falciparum malaria, but efﬁcacy
was inferior to 7-d artesunate monotherapy and was unsat-
isfactory for general deployment in this area. Reduced
efﬁcacy probably results from lowered drug concentrations
in later pregnancy in the presence of relatively resistant
parasites. A higher-dose regimen may be needed to treat
pregnant women effectively and should now be evaluated.
Longer follow-up is needed when assessing antimalarial drugs
in pregnancy as recrudescences may occur months after
administration of rapidly eliminated drugs.
Supporting Information
Text S1. CONSORT Checklist
Found at doi:10.1371/journal.pmed.0050253.sd001 (115 KB PDF).
Text S2. Trial Protocol
Artemether-lumefantrine treatment of multidrug-resistant falcipa-
rum malaria in pregnancy: a pilot study.
Found at doi:10.1371/journal.pmed.0050253.sd002 (198 KB DOC).
Acknowledgments
We would like to express our sincere thanks to the pregnant women,
doctors, midwives, medics, nurses, lab technicians, home-visitors,
cleaners, drivers, and logistical and administrative teams of SMRU
and MORU who made this detailed work possible. Many thanks to
Anna Annerberg and Benjamas Kamanikom for help with measuring
lumefantrine concentrations, and Joel Tarning and Mara Leimanis
for their contribution to this manuscript.
Author contributions. RM, NJW, and FN developed the study
protocol. RM, SOT, EAA, MP, JV, LP, and KW oversaw the
implementation of the trial, assisted with the data analysis and
drafting of the manuscript. LK oversaw the field laboratory work and
analysis of the malaria smear results, MB and N Laochan undertook
the PCR analysis, and N Lindegardh the lumefantrine analysis. EAA,
PS, NJW, and FN contributed to the monitoring of the trial and
drafting of the manuscript.
References
1. Brabin BJ, Verhoeff F (2002) The contribution of malaria. In: Maclean AB,
Nielson editors. Maternal morbidity and mortality. London: Royal College
of Obstetricians and Gynaecologists. pp. 65–78.
2. Granja AC, Machungo F, Gomes A, Bergstrom S, Brabin B (1998) Malaria-
related maternal mortality in urban Mozambique. Ann Trop Med Parasitol
92: 257–263.
3. Nosten F, ter Kuile F, Maelankirri L, Decludt B, White NJ (1991) Malaria
during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med
Hyg 85: 424–429.
4. Dolan G, ter Kuile FO, Jacoutot V, White NJ, Luxemburger C, et al. (1993)
Bed nets for the prevention of malaria and anaemia in pregnancy. Trans R
Soc Trop Med Hyg 87: 620–626.
5. McGready R, Simpson JA, Htway M, White NJ, Nosten F, et al. (2001) A
double-blind randomized therapeutic trial of insect repellents for the
prevention of malaria in pregnancy. Trans R Soc Trop Med Hyg 95: 137–138.
6. McGready R, Brockman A, Cho T, Cho D, van Vugt M, et al. (2000)
Randomized comparison of meﬂoquine-artesunate versus quinine in the
treatment of multidrug-resistant falciparum malaria in pregnancy. Trans R
Soc Trop Med Hyg 94: 689–693.
7. McGready R, Ashley EA, Moo E, Cho T, Barends M, et al. (2005) A
randomized comparison of artesunate-atovaquone-proguanil versus qui-
nine in treatment for uncomplicated falciparum malaria during pregnancy.
J Infect Dis 192: 846–853.
8. McGready R, Cho T, Samuel, Villegas L, Brockman A, et al. (2001)
Randomized comparison of quinine-clindamycin versus artesunate in the
treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg
95: 651–656.
9. WHO (2006) WHO guidelines for the treatment of malaria. Geneva: World
Health Organization. WHO/HTM/MAL 2006/1108. Available: http://www.
who.int/malaria/treatmentguidelines.html. Accessed 19 November 2008.
10. van Vugt M, Looareesuwan S, Wilairatana P, McGready R, Villegas L, et al.
(2000) Artemether-lumefantrine for the treatment of multidrug-resistant
falciparum malaria. Trans R Soc Trop Med Hyg 94: 545–548.
11. Hutagalung R, Paiphun L, Ashley EA, McGready R, Brockman A, et al.
(2005) A randomized trial of artemether-lumefantrine versus meﬂoquine-
artesunate for the treatment of uncomplicated multi-drug resistant
Plasmodium falciparum on the western border of Thailand. Malar J 4: 46.
12. Bakshi R, Hermeling-Fritz I, Gathmann I, Alteri E (2000) An integrated
assessment of the clinical safety of artemether-lumefantrine: a new oral
ﬁxed-dose combination antimalarial drug. Trans R Soc Trop Med Hyg 94:
419–424.
13. Nosten F, McGready R, Mutabingwa T (2007) Case management of malaria
in pregnancy. Lancet Infect Dis 7: 118–125.
14. Wang TY (1989) Follow-up observation on the therapeutic effects and
remote reactions of artemisinin (Qinghaosu) and artemether in treating
malaria in pregnant woman. J Tradit Chin Med 9: 28–30.
15. Chen LJ, Wang MY, Sun WK, Liu MZ (1984) Embryotoxicity and
teratogenicity studies on artemether in mice, rats and rabbits. Zhongguo
Yao Li Xue Bao 5: 118–122.
16. Clark RL, Arima A, Makori N, Nakata Y, Bernard F, et al. (2008) Artesunate:
developmental toxicity and toxicokinetics in monkeys. Birth Defects Res B
Dev Reprod Toxicol 83: 418–434.
17. Dellicour S, Hall S, Chandramohan D, Greenwood B (2007) The safety of
artemisinins during pregnancy: a pressing question. Malar J 6: 15.
18. McGready R, Cho T, Keo NK, Thwai KL, Villegas L, et al. (2001) Artemisinin
antimalarials in pregnancy: a prospective treatment study of 539 episodes
of multidrug-resistant Plasmodium falciparum. Clin Infect Dis 33: 2009–
2016.
19. WHO (2003) Assessment of the safety of artemisinin compounds in




20. Ward SA, Sevene EJ, Hastings IM, Nosten F, McGready R (2007)
Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharma-
covigilance. Lancet Infect Dis 7: 136–144.
21. Green MD, van Eijk AM, van Ter Kuile FO, Ayisi JG, Parise ME, et al. (2007)
Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and
uninfected pregnant women in Western Kenya. J Infect Dis 196: 1403–1408.
22. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, et al. (2006)
Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing
implications. Clin Pharmacol Ther 80: 582–596.
23. McGready R, Stepniewska K, Lindegardh N, Ashley EA, La Y, et al. (2006)
The pharmacokinetics of artemether and lumefantrine in pregnant women
with uncomplicated falciparum malaria. Eur J Clin Pharmacol 62: 1021–
1031.
24. Dubowitz LM, Dubowitz V, Goldberg C (1970) Clinical assessment of
gestational age in the newborn infant. J Pediatr 77: 1–10.
25. McGready R, Simpson J, Panyavudhikrai S, Loo S, Mercuri E, et al. (2000)
Neonatal neurological testing in resource-poor settings. Ann Trop Paediatr
20: 323–336.
26. Haataja L, McGready R, Arunjerdja R, Simpson JA, Mercuri E, et al. (2002)
A new approach for neurological evaluation of infants in resource-poor
settings. Ann Trop Paediatr 22: 355–368.
27. National Cancer Institute CTEP (2006) The NCI Common Terminology
Criteria for Adverse Events v3.0 pp. Available: http://ctep.cancer.gov/forms/
CTCAEv3.pdf. Accessed 19 November 2008.
28. Brockman A, Paul RE, Anderson TJ, Hackford I, Phaiphun L, et al. (1999)
Application of genetic markers to the identiﬁcation of recrudescent
Plasmodium falciparum infections on the northwestern border of Thailand.
Am J Trop Med Hyg 60: 14–21.
29. Annerberg A, Singtoroj T, Tipmanee P, White NJ, Day NP, et al. (2005) High
throughput assay for the determination of lumefantrine in plasma. J
Chromatogr B Analyt Technol Biomed Life Sci 822: 330–333.
30. White NJ, van Vugt M, Ezzet F (1999) Clinical pharmacokinetics and
PLoS Medicine | www.plosmedicine.org December 2008 | Volume 5 | Issue 12 | e253 1714
RCT AL Versus AS7 Treatment in Pregnancypharmacodynamics and pharmacodynamics of artemether-lumefantrine.
Clin Pharmacokinet 37: 105–125.
31. van Vugt M, Ezzet F, Phaipun L, Nosten F, White NJ (1998) The relationship
between capillary and venous concentrations of the antimalarial drug
lumefantrine (benﬂumetol). Trans R Soc Trop Med Hyg 92: 564–565.
32. Brockman A, Price RN, van Vugt M, Heppner DG, Walsh D, et al. (2000)
Plasmodium falciparum antimalarial drug susceptibility on the north-western
border of Thailand during ﬁve years of extensive use of artesunate-
meﬂoquine. Trans R Soc Trop Med Hyg 94: 537–544.
33. Price RN, Cassar C, Brockman A, Duraisingh M, van Vugt M, et al. (1999)
The pfmdr1 gene is associated with a multidrug-resistant phenotype in
Plasmodium falciparum from the western border of Thailand. Antimicrob
Agents Chemother 43: 2943–2949.
34. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, et al. (2004)
Meﬂoquine resistance in Plasmodium falciparum and increased pfmdr1 gene
copy number. Lancet 364: 438–447.
35. Uhlemann AC, McGready R, Ashley EA, Brockman A, Singhasivanon P, et
al. (2007) Intrahost selection of Plasmodium falciparum pfmdr1 alleles after
antimalarial treatment on the northwestern border of Thailand. J Infect
Dis 195: 134–141.
36. Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, et al.
(2006) Molecular and pharmacological determinants of the therapeutic
response to artemether-lumefantrine in multidrug-resistant Plasmodium
falciparum malaria. Clin Infect Dis 42: 1570–1577.
37. McGready R, Stepniewska K, Edstein MD, Cho T, Gilveray G, et al. (2003)
The pharmacokinetics of atovaquone and proguanil in pregnant women
with acute falciparum malaria. Eur J Clin Pharmacol 59: 545–552.
38. McGready R, Stepniewska K, Seaton E, Cho T, Cho D, et al. (2003)
Pregnancy and use of oral contraceptives reduces the biotransformation of
proguanil to cycloguanil. Eur J Clin Pharmacol 59: 553–557.
39. McGready R, Stepniewska K, Ward SA, Cho T, Gilveray G, et al. (2006)
Pharmacokinetics of dihydroartemisinin following oral artesunate treat-
ment of pregnant women with acute uncomplicated falciparum malaria.
Eur J Clin Pharmacol 62: 367–371.
40. Stepniewska K, Taylor WR, Mayxay M, Price R, Smithuis F, et al. (2004) In
vivo assessment of drug efﬁcacy against Plasmodium falciparum malaria:
duration of follow-up. Antimicrob Agents Chemother 48: 4271–4280.
41. Price RN, Dorsey G, Ashley EA, Barnes KI, Baird JK, et al. (2007) World
Antimalarial Resistance Network I: clinical efﬁcacy of antimalarial drugs.
Malar J 6: 119.
42. Kalilani L, Mofolo I, Chaponda M, Rogerson SJ, Alker AP, et al. (2007) A
randomized controlled pilot trial of azithromycin or artesunate added to
sulfadoxine-pyrimethamine as treatment for malaria in pregnant women.
PLoS ONE 2: e1166. doi:10.1371/journal.pone.0001166.
43. Guyatt HL, Snow RW (2001) The epidemiology and burden of Plasmodium
falciparum-related anemia among pregnant women in sub-Saharan Africa.
Am J Trop Med Hyg 64: 36–44.
44. Price R, van Vugt M, Nosten F, Luxemburger C, Brockman A, et al. (1998)
Artesunate versus artemether for the treatment of recrudescent multidrug-
resistant falciparum malaria. Am J Trop Med Hyg 59: 883–888.
45. Luxemburger C, McGready R, Kham A, Morison L, Cho T, et al. (2001)
Effects of malaria during pregnancy on infant mortality in an area of low
malaria transmission. Am J Epidemiol 154: 459–465.
46. McGready R, Keo NK, Villegas L, White NJ, Looareesuwan S, et al. (2003)
Artesunate-atovaquone-proguanil rescue treatment of multidrug-resistant
Plasmodium falciparum malaria in pregnancy: a preliminary report. Trans R
Soc Trop Med Hyg 97: 592–594.
47. Ashley EA, Stepniewska K, Lindegardh N, McGready R, Annerberg A, et al.
(2007) Pharmacokinetic study of artemether-lumefantrine given once daily
for the treatment of uncomplicated multidrug-resistant falciparum
malaria. Trop Med Int Health 12: 201–208.
48. van Vugt M, Wilairatana P, Gemperli B, Gathmann I, Phaipun L, et al.
(1999) Efﬁcacy of six doses of artemether-lumefantrine (benﬂumetol) in
multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 60:
936–942.
Editors’ Summary
Background. Plasmodium falciparum, a mosquito-borne parasite that
causes malaria, kills nearly one million people every year. Although most
deaths occur among young children, malaria during pregnancy is also an
important public-health problem. In areas where malaria transmission is
high (stable transmission), women acquire a degree of immunity.
Although less symptomatic than women who lack natural protection,
their babies are often small and sickly because malaria-related anemia
(lack of red blood cells) and parasites in the placenta limit the nutrients
supplied to the baby before birth. By contrast, in areas where malaria
transmission is low (unstable transmission or sporadic outbreaks),
women have little immunity to P. falciparum. If these women become
infected during pregnancy, ‘‘uncomplicated’’ malaria (fever, chills, and
anemia) can rapidly progress to ‘‘severe’’ malaria (in which vital organs
are damaged), which can be fatal to the mother and/or her unborn child
unless prompt and effective treatment is given.
Why Was This Study Done? Malaria parasites are now resistant to many
of the older antimalarial drugs (for example, quinine). So, since 2006, the
World Health Organization (WHO) has recommended that uncompli-
cated malaria during the second and third trimester of pregnancy is
treated with short course (3 d) fixed-dose artemisinin combination
therapy (ACT; quinine is still used in early pregnancy because it is not
known whether ACT damages fetal development, which mainly occurs
during the first 3 mo of pregnancy). Artemisinin derivatives are fast-
acting antimalarial agents that are used in combination with another
antimalarial drug to reduce the chances of P. falciparum becoming
resistant to either drug. The most widely used fixed-dose ACT is
artemether–lumefantrine (AL) but, although several trials have examined
the safety and efficacy of this treatment in non-pregnant women, little is
known about how well it works in pregnant women. In this study, the
researchers compare the efficacy, tolerability, and safety of AL with a 7-d
course of artesunate monotherapy (AS7; another artemisinin derivative)
in the treatment of uncomplicated malaria in pregnancy in northwest
Thailand, an area with unstable but highly drug resistant malaria
transmission.
What Did the Researchers Do and Find? The researchers enrolled 253
women with uncomplicated malaria during the second and third
trimesters of pregnancy into their open-label trial (a trial in which the
patients and their health-care workers know who is receiving which drug
regimen). Half the women received each type of treatment. The trial’s
main outcome was the ‘‘PCR-adjusted cure rate’’ at delivery or 42 d after
treatment if this occurred after delivery. This cure rate was assessed by
examining blood smears for parasites and then using a technique called
PCR to determine which cases of malaria were new infections (classified
as treatment successes along with negative blood smears) and which
were recurrences of an old infection (classified as treatment failures). The
PCR-adjusted cure rates were 89.7% and 81.2% for AS7 and AL,
respectively. Both treatments were well tolerated, few side effects were
seen with either treatment, and infant health and development at birth
and up to 1 y old were similar with both regimens. Finally, an analysis of
blood samples taken 7 d after treatment with AL showed that blood
levels of lumefantrine were below those previously associated with
treatment failure in about a third of the women tested.
What Do These Findings Mean? Although these findings indicate that
the AL regimen is a well tolerated and safe treatment for uncomplicated
malaria in pregnant women living in northwest Thailand, the efficacy of
this treatment was lower than that of artesunate monotherapy. In fact,
neither treatment reached the 90% cure rate recommended by WHO for
ACTs and it is likely that cure rates in a more realistic situation (that is,
not in a trial where efforts are made to make sure everyone completes
their treatment) would be even lower. The findings also suggest that the
reduced efficacy of the AL regimen in pregnant women compared to the
efficacy previously seen in non-pregnant women may be caused by
lower drug blood levels during pregnancy. Thus, a higher-dose AL
regimen (or an alternative ACT) may be needed to successfully treat
uncomplicated malaria during pregnancy.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050253.
  The MedlinePlus encyclopedia contains a page on malaria (in English
and Spanish)
  Information is available from the World Health Organization on malaria
(in several languages), and their 2006 Guidelines for the Treatment of
Malaria includes specific recommendations for the treatment of
pregnant women
  The US Centers for Disease Control and Prevention provide informa-
tion on malaria and on malaria during pregnancy (in English and
Spanish)
  Information is available from the Roll Back Malaria Partnership on
malaria during pregnancy, on artemisinin-based combination
therapies, and on malaria in Thailand
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